Drug Trial Radar · NCT03552757
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,210
Actual
Start
Jun 4, 2018
Primary completion
Mar 24, 2020
Study completion May 1, 2020
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jun 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk of type 2 diabetes. Therefore, weight loss has shown to have a beneficial impact on the blood sugar levels. The participant will either get semaglutide or "dummy" medicine - which treatment the participant get is decided by chance. The participant will need to take 2 injections at the same time once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years
Conditions
- Obesity
- Overweight
Interventions
Semaglutide 1.0 mgDrug
Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
Semaglutide 2.4 mgDrug
Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
Placebo I (Semaglutide)Drug
S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
Placebo II (Semaglutide)Drug
S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Body Weight (%) - Semaglutide 2.4 mg Versus PlaceboTime frame: Baseline (week 0) to week 68
- Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus PlaceboTime frame: At week 68
Locations
147 sites in 13 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Buena Park, California
Novo Nordisk Investigational Site
Concord, California
Novo Nordisk Investigational Site
Fresno, California
Novo Nordisk Investigational Site
Lomita, California
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Mission Hills, California
Novo Nordisk Investigational Site
Spring Valley, California
Novo Nordisk Investigational Site
Tarzana, California
Novo Nordisk Investigational Site
Golden, Colorado
Novo Nordisk Investigational Site
Clearwater, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Kissimmee, Florida
Novo Nordisk Investigational Site
St. Petersburg, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Novo Nordisk Investigational Site
Alpharetta, Georgia
Novo Nordisk Investigational Site
Atlanta, Georgia
Novo Nordisk Investigational Site
Roswell, Georgia
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Springfield, Illinois
Novo Nordisk Investigational Site
West Des Moines, Iowa
Novo Nordisk Investigational Site
Topeka, Kansas
Novo Nordisk Investigational Site
Lexington, Kentucky
Novo Nordisk Investigational Site
Louisville, Kentucky
Novo Nordisk Investigational Site
Minneapolis, Minnesota
Novo Nordisk Investigational Site
Olive Branch, Mississippi
Novo Nordisk Investigational Site
Butte, Montana
Novo Nordisk Investigational Site
Lawrenceville, New Jersey
Novo Nordisk Investigational Site
Chapel Hill, North Carolina
Novo Nordisk Investigational Site
Greensboro, North Carolina
Novo Nordisk Investigational Site
Greenville, North Carolina
Novo Nordisk Investigational Site
Hickory, North Carolina
Novo Nordisk Investigational Site
Salisbury, North Carolina
Novo Nordisk Investigational Site
Wilmington, North Carolina
Novo Nordisk Investigational Site
Wadsworth, Ohio
Novo Nordisk Investigational Site
Anderson, South Carolina
Novo Nordisk Investigational Site
Mt. Pleasant, South Carolina
Novo Nordisk Investigational Site
Bristol, Tennessee
Novo Nordisk Investigational Site
Nashville, Tennessee
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.